DVA DaVita Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against DaVita Inc. - DVA

NEW YORK--(BUSINESS WIRE)--

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of DaVita Inc. (NYSE:DVA) resulting from allegations that DaVita may have issued materially misleading business information to the investing public.

On January 6, 2017, after the close of trading, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis. On this news, shares of DaVita fell approximately 4% during intraday trading on January 9, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by DaVita investors. If you purchased shares of DaVita before January 9, 2017, please visit the firm’s website at http://www.rosenlegal.com/cases-1026.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
09/01/2017

Underlying

DVADaVita Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DaVita Inc.

EUR 152.87
DVA DAVITA INC.

DaVita Inc.: Update to credit analysis

Our credit view of this issuer reflects its strong free cash flow and its considerable scale and strong US market position, against its track record of debt-funded share repurchases.

12/11/25 December 11, 2025 1 EN
DVA DAVITA INC.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of DaVita Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 8 December 2025 in which we reassessed the appropriateness of the ratings in the context of the...

12/10/25 December 10, 2025 1 EN
Free Trial
DVA DAVITA INC.

Davita Inc: 1 director

A director at Davita Inc sold 2,351 shares at 150.000USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

07/25/25 July 25, 2025 1 EN
EUR 152.87
DVA DAVITA INC.

Moody's Ratings assigns Ba3 rating to DaVita's proposed senior unsecur...

Moody's Ratings (Moody's) assigned a Ba3 rating to DaVita Inc.'s ("DaVita" or "the company") proposed senior unsecured notes. There is no change to the company's existing ratings, including the Ba2 corporate family rating (CFR), Ba2-PD probability of default rating (PDR), Ba1 senior secured bank cre...

05/20/25 May 20, 2025 1 EN
EUR 212.33
DVA DAVITA INC.

DaVita Inc.: Update to credit analysis

Our credit view of this issuer reflects its strong free cash flow and its considerable scale and strong US market position, against its track record of debt-funded share repurchases.

01/24/25 January 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch